Wedbush reiterates Oric Pharmaceuticals stock rating on trial data
Wedbush reiterated an Outperform rating and $14.00 price target for ORIC Pharmaceuticals (ORIC) after its Q3 2026 earnings update. The stock is near its 52-week low at $7.52. InvestingPro values ORIC at $8.57. The company shared positive trial data for rinzimetostat in prostate cancer, with Phase 3 studies ongoing. BTIG and Stifel also issued Buy ratings with higher price targets.
How this was made
The 30-second read
Why it matters
The piece is a catalyst-driven analyst reiteration tied to specific longer-term rinzimetostat progression-free survival estimates and safety, plus a timeline for upcoming Phase 3-related readouts.
Market read
Traders get a probability-weighting update for rinzimetostat based on longer-term radiographic progression-free survival durability and a clearer near-term clinical timeline, reinforced by reiterated bullish sell-side stance.
What to watch
The article provides follow-up estimates and safety but does not include trial endpoints like overall survival or regulatory milestones, leaving material uncertainty around ultimate clinical and commercial impact.
Background
Oric Pharmaceuticals is advancing rinzimetostat in metastatic castration-resistant prostate cancer, with Phase 3 Himalayas-1 enrollment beginning post-abiraterone and a planned MEVPRO-1 readout for mevrometostat.
Ticker impact
Wedbush reiterated Outperform and a $14 target after Oric’s Q3 update with longer-term rinzimetostat trial follow-up and Phase 3 enrollment timing.
Likely upward bias as traders price improved durability/safety in rinzimetostat and the upcoming MEVPRO-1 readout.
The article highlights new longer-term radiographic progression-free survival and safety (no Grade 4/5), plus Phase 3 Himalayas-1 enrollment starting and a February 2027 MEVPRO-1 readout, which can shift probability-weighting for the program.
Market effects
Adds incremental read-through for prostate cancer oncology trial expectations and competitive positioning among next-gen castration-resistant prostate cancer therapies.
Limited, primarily impacts US biotech sentiment and small-cap growth risk appetite.
Moderate, as ESMO-related poster activity and multinational trial cohorts can influence global biotech risk pricing.
Counterpoint
Competition from other agents (cited as emerging) could cap upside if efficacy signals do not translate into a clear differentiation versus next-gen rivals.
Key entities
- companyOric Pharmaceuticals
NASDAQ-listed biotech advancing rinzimetostat; subject of the Wedbush rating reiteration and trial-data update.
- drug_programrinzimetostat
Oric’s therapy whose longer-term follow-up data are highlighted in post-abiraterone and post-AR inhibitor cohorts.
- clinical_trialHimalayas-1
Phase 3 study beginning enrollment in post-abiraterone metastatic castration-resistant prostate cancer.
- clinical_trialMEVPRO-1
Upcoming readout for mevrometostat referenced as a near-term indicator for rinzimetostat.
- competitorJNJ-6143
Emerging competitive therapy cited by Wedbush as a potential overhang.

